Key Takeaways
- • Digital health startups raised nearly $11 billion in 2023, representing a steep decline from pandemic-era peaks, but Bessemer Venture Partners' Andrew Hedin characterizes 2021-2022 funding levels as anomalies rather than sustainable norms, positioning current activity as a return to historical normalcy.
- • The venture capital market has stabilized at levels significantly above pre-pandemic baselines from six to seven years ago, indicating that despite year-over-year declines, the digital health funding environment remains materially elevated on an absolute basis.
- • High-quality startups capable of demonstrating proven business models and measurable value will continue to attract capital in 2024, as investor focus has shifted from quantity-based deployment toward quality-based underwriting and return optimization.
- • Bessemer Venture Partners expects funding momentum in 2024 to remain consistent with 2023 activity levels—characterized as moderate and normalized—rather than experiencing significant acceleration or further contraction.
Summary
Digital health funding declined substantially in 2023 to approximately $11 billion, according to Rock Health's latest report, marking a dramatic pullback from the elevated investment levels of 2021 and 2022. However, Andrew Hedin, a partner at Bessemer Venture Partners, contextualizes this downturn not as a sector crisis but as a correction toward historical norms. Hedin emphasizes that despite year-over-year declines, absolute funding levels remain significantly ahead of where the sector stood six to seven years prior to the pandemic surge.
Hedin's framework recharacterizes the 2021-2022 period as an anomaly driven by extraordinary pandemic-era conditions rather than sustainable market fundamentals. This distinction is strategically important for investors evaluating sectoral health: the current environment represents a normalization of venture capital deployment patterns, not a structural collapse in digital health investment appetite. Activity levels in the latter half of 2023 and early 2024 reflect what Hedin describes as a "return to normalcy in terms of activity and pacing," suggesting investor confidence remains intact despite quantitative declines.
Looking forward to 2024, Bessemer's outlook projects continued moderation rather than dramatic shifts. Hedin indicates the sector will "see more of the same going into 2024," implying stable but measured funding availability. The critical differentiator for capital allocation going forward is startup quality and demonstrable business value. Investors are increasingly selective, focusing capital on companies that can substantiate commercial viability, unit economics, and pathway to profitability—a material shift from the more indiscriminate deployment patterns of the 2021-2022 period. This selective posture creates a bifurcated market where high-quality startups continue to access capital while those lacking differentiation or proven traction face meaningful headwinds.
Hedin's framework recharacterizes the 2021-2022 period as an anomaly driven by extraordinary pandemic-era conditions rather than sustainable market fundamentals. This distinction is strategically important for investors evaluating sectoral health: the current environment represents a normalization of venture capital deployment patterns, not a structural collapse in digital health investment appetite. Activity levels in the latter half of 2023 and early 2024 reflect what Hedin describes as a "return to normalcy in terms of activity and pacing," suggesting investor confidence remains intact despite quantitative declines.
Looking forward to 2024, Bessemer's outlook projects continued moderation rather than dramatic shifts. Hedin indicates the sector will "see more of the same going into 2024," implying stable but measured funding availability. The critical differentiator for capital allocation going forward is startup quality and demonstrable business value. Investors are increasingly selective, focusing capital on companies that can substantiate commercial viability, unit economics, and pathway to profitability—a material shift from the more indiscriminate deployment patterns of the 2021-2022 period. This selective posture creates a bifurcated market where high-quality startups continue to access capital while those lacking differentiation or proven traction face meaningful headwinds.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.